

AMENDMENTS TO THE CLAIMS

1. (Currently amended) An agonist antibody that specifically binds to a native sequence mouse or human TACI receptor, wherein said agonist antibody -and inhibits B cell proliferation and activates NF-kB, and wherein the antibody does not inhibit a native sequence mouse or human BLyS binding to said TACI receptor.
2. (Currently amended) The antibody of claim 1, wherein the antibody does not bind to a native sequence mouse or human BCMA receptor.
3. (Original) The antibody of claim 1, wherein the antibody is a monoclonal antibody.
4. (Currently amended) The monoclonal antibody of claim 3, wherein said monoclonal antibody comprises ~~the variable domain of the 6D11.3.1 antibody produced by the hybridoma deposited with ATCC as accession number PTA-4299 or~~ the variable domain of the 7B6.15.11 antibody produced by the hybridoma deposited with ATCC as accession number PTA-5000.

5-13. (Cancelled)

14. (Currently amended) The monoclonal antibody of claim 3, wherein the antibody competitively inhibits binding of ~~the 6D11.3.1 monoclonal antibody produced by the hybridoma deposited as ATCC PTA-4299 or~~ the 7B6.15.11 monoclonal antibody produced by the hybridoma deposited as ATCC PTA-5000) to said TACI receptor.

15-24. (Cancelled)

25. (Currently amended) The antibody according to claim 1 ~~5~~, wherein the antibody is the 7B6.15.11 antibody produced by the hybridoma cell line deposited with ATCC as Accession

No. PTA-5000.

26-27. (Cancelled)

28. (Currently amended) A hybridoma cell line which produces monoclonal antibody 7B6.15.11 and was as deposited with ATCC as 7B6.15.11 (Accession No. PTA-5000).

29-30. (Cancelled)

31. (Currently amended) The antibody of claim 1, wherein the antibody comprises the three complementarity determining regions (CDRs) of the heavy chain variable domain and the three CDRs of the light chain variable domain sequence derived from the variable domain of the 7B6.15.11 antibody produced by the hybridoma deposited with ATCC as accession number PTA-5000 or a sequence derived from the variable domain of the 6D11.3.1 antibody produced by the hybridoma deposited with ATCC as accession number PTA-4299.

32-36. (Cancelled)

37. (Previously presented) The antibody of claim 1, which is glycosylated.

38. (Previously presented) The antibody of claim 1, which is unglycosylated.

39-48. (Cancelled)

49. (Withdrawn) The antibody of claim 1, wherein the antibody is a chimeric antibody.

50. (Withdrawn) The antibody of claim 1, wherein the antibody is linked to one or more non-proteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol and polyoxyalkylene.

51. (Previously presented) The antibody of claim 1, wherein the antibody is linked to a cytotoxic agent or enzyme.

52. (Withdrawn) The antibody of claim 1, wherein the antibody is linked to a radioisotope, fluorescent compound or chemiluminescent compound.

53. (Previously presented) The antibody of claim 1, wherein the antibody is a humanized antibody

54. (Previously presented) The antibody of claim 1, wherein the antibody is an antibody fragment.

55. (Previously presented) The antibody of claim 1, wherein the native sequence human TACI receptor comprises amino acids 2 to 166 of SEQ ID NO: 3.

56. (Cancelled)